Large gap with delayed quotes
|
Last quote
09/11/2026
-
17:30:17
|
Bid
09/11/2026 -
17:40:00
|
Bid Volume |
Ask
09/11/2026 -
17:40:00
|
Ask Volume |
|---|---|---|---|---|
|
11.34
-0.06
(
-0.53% )
|
11.10
|
751 |
12.16
|
244 |
Analysis date: 08.09.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 07.08.2026.
Interest
Strong
Strong
Three stars since 04.09.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 04.09.2026 at a price of 12.02.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 14.08.2026.
4wk Rel Perf
0.96%
0.96%
The four-week dividend-adjusted performance versus STOXX600 is .
Sensibility
High
High
The stock has been on the high-sensitivity level since 21.04.2026.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -1.03%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.03%.
Mkt Cap in $bn
0.30
0.30
With a market capitalization <$2bn, NEWRON PHARMACEUTICALS SPA is considered a small-cap stock.
G/PE Ratio
0.81
0.81
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential:
LT P/E
84.22
84.22
The estimated PE is for the year 2027.
LT Growth
68.21%
68.21%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
3
3
Over the last seven weeks, an average of 3 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
63
63
For 1% of index variation, the stock varies on average by 0.63%.
Correlation
0.14
0.14
Stock movements are totally independent of index variations.
Value at Risk
5.22
5.22
The value at risk is estimated at CHF 5.22. The risk is therefore 43.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
24.04.2018
24.04.2018